Recent studies on the antimicrobial peptides lactoferricin and lactoferrampin

Current Molecular Medicine

Volumn 14, Issue 9, 2014, Pages 1139-1154

  Yin, C ^a   Wong, J H ^a   Ng, T B ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antimicrobial peptide; Lactoferrampin; Lactoferricin; Mechanism; Modification

Indexed keywords

AMINO ACID; COLLAGENASE 3; FIBROBLAST GROWTH FACTOR 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LACTOFERRAMPIN; LACTOFERRICIN; MITOGEN ACTIVATED PROTEIN KINASE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN KINASE B; STROMELYSIN; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; LACTOFERRICIN B; LACTOFERRIN; PEPTIDE FRAGMENT;

ACETALIZATION; AMIDATION; AMINO ACID SYNTHESIS; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL STRUCTURE; CHIMERA; CYCLIZATION; DISULFIDE BOND; HUMAN; METHYLATION; MOLECULAR STABILITY; NONHUMAN; VIRUS ENTRY; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; MOLECULAR GENETICS; PHYSIOLOGY; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; HUMANS; LACTOFERRIN; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION;

EID: 84926324375     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524014666141015151749     Document Type: Article

References (133)

1. Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 1992; 73: 472-9.
2. van der Kraan MI, Groenink J, Nazmi K, Veerman EC, Bolscher JG, Nieuw Amerongen AV. Lactoferrampin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides 2004; 25: 177-83.
3. Haney EF, Nazmi K, Lau F, Bolscher JG, Vogel HJ. Novel lactoferrampin antimicrobial peptides derived from human lactoferrin. Biochimie 2009; 91: 141-54.
4. Andersen JH, Osbakk SA, Vorland LH, Traavik T, Gutteberg TJ. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res 2001; 51: 141-9.
5. Andersen JH, Jenssen H, Gutteberg TJ. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res 2003; 58: 209-15.
6. Bellamy W, Wakabayashi H, Takase M, Kawase K, Shimamura S, Tomita M. Killing of Candida-Albicans by Lactoferricin-B, a Potent Antimicrobial Peptide Derived from the N-Terminal Region of Bovine Lactoferrin. Med Microbiol Immunol 1993; 182: 97-105.
7. Bolscher J, Nazmi K, van Marle J, van 't Hof W, Veerman E. Chimerization of lactoferricin and lactoferrampin peptides strongly potentiates the killing activity against Candida albicans. Biochem Cell Biol 2012; 90: 378-88.
8. Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: a lactoferrinderived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 2005; 62: 2588-98.
9. Samuelsen O, Haukland HH, Kahl BC, et al. Staphylococcus aureus small colony variants are resistant to the antimicrobial peptide lactoferricin B. J Antimicrob Chemoth 2005; 56: 1126-9.
10. Brock JH. The physiology of lactoferrin. Biochem Cell Biol 2002; 80: 1-6.
11. Tuccari G, Barresi G. Lactoferrin in human tumours: immunohistochemical investigations during more than 25 years. Biometals 2011; 24: 775-84.
12. Blanc B, Isliker H. [Isolation and characterization of the red siderophilic protein from maternal milk: lactotransferrin]. Bull Soc Chim Biol (Paris) 1961; 43: 929-43.
13. Davidson LA, Lonnerdal B. Isolation and characterization of rhesus monkey milk lactoferrin. Pediatr Res 1986; 20: 197-201.
14. Khan JA, Kumar P, Paramasivam M, et al. Camel lactoferrin, a transferrin-cum-lactoferrin: Crystal structure of camel apolactoferrin at 2.6 angstrom resolution and structural basis of its dual role. J Mol Biol 2001; 309: 751-61.
15. Kumar S, Bhatia KL. Characterization of Buffalo Lactotransferrin by Polyacrylamide-Gel Electrophoresis in 6-M Urea. J Chromatogr-Biomed 1988; 434: 228-31.
16. Masson PL, Heremans JF. Lactoferrin in Milk from Different Species. Comp Biochem Physiol B 1971; 39: 119-29.
17. Anderson BF, Baker HM, Norris GE, Rumball SV, Baker EN. Apolactoferrin Structure Demonstrates Ligand-Induced Conformational Change in Transferrins. Nature 1990; 344: 784-7.
18. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. Identification of the Bactericidal Domain of Lactoferrin. Biochim Biophys Acta 1992; 1121: 130-6.
19. Kuwata H, Yip TT, Tomita M, Hutchens TW. Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin. Biochim Biophys Acta 1998; 1429: 129-41.
20. Furlund CB, Ulleberg EK, Devold TG, et al. Identification of lactoferrin peptides generated by digestion with human gastrointestinal enzymes. J Dairy Sci 2013; 96: 75-88.
21. Vorland LH, Ulvatne H, Andersen J, et al. Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand J Infect Dis 1998; 30: 513-7.
22. Hunter HN, Demcoe AR, Jenssen H, Gutteberg TJ, Vogel HJ. Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob Agents Chemother 2005; 49: 3387-95.
23. Dionysius DA, Milne JM. Antibacterial peptides of bovine lactoferrin: Purification and characterization. J Dairy Sci 1997; 80: 667-74.
24. Rey MW, Woloshuk SL, Deboer HA, Pieper FR. Complete Nucleotide-Sequence of Human Mammary-Gland Lactoferrin. Nucleic Acids Res 1990; 18: 5288.
25. Pierce A, Colavizza D, Benaissa M, et al. Molecular-Cloning and Sequence-Analysis of Bovine Lactotransferrin. Eur J Biochem 1991; 196: 177-84.
26. Hwang PM, Zhou N, Shan X, Arrowsmith CH, Vogel HJ. Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 1998; 37: 4288-98.
27. Bolscher JGM, van der Kraan MIA, Nazmi K, et al. A oneenzyme strategy to release an antimicrobial peptide from the LFampin-domain of bovine lactoferrin. Peptides 2006; 27: 1-9.
28. Berkhout B, van Wamel JLB, Beljaars L, Meijer DKF, Visser S, Floris R. Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res 2002; 55: 341-55.
29. Di Biase AM, Pietrantoni A, Tinari A, et al. Heparininteracting sites of bovine lactoferrin are involved in antiadenovirus activity. J Med Virol 2003; 69: 495-502.
30. McCann KB, Lee A, Wan J, Roginski H, Coventry MJ. The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures. J Appl Microbiol 2003; 95: 1026-33.
31. Mistry N, Drobni P, Nasland J, Sunkari VG, Jenssen H, Evander M. The anti-papillomavirus activity of human and bovine lactoferricin. Antiviral Res 2007; 75: 258-65.
32. Pietrantoni A, Ammendolia MG, Tinari A, Siciliano R, Valenti P, Superti F. Bovine lactoferrin peptidic fragments involved in inhibition of Echovirus 6 in vitro infection. Antiviral Res 2006; 69: 98-106.
33. Shestakov A, Jenssen H, Nordstrom I, Eriksson K. Lactoferricin but not lactoferrin inhibit herpes simplex virus type 2 infection in mice. Antiviral Res 2012; 93: 340-5.
34. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1992; 1121: 130-6.
35. Hoek KS, Milne JM, Grieve PA, Dionysius DA, Smith R. Antibacterial activity in bovine lactoferrin-derived peptides. Antimicrob Agents Chemother 1997; 41: 54-9.
36. Yamauchi K, Tomita M, Giehl TJ, Ellison RT, 3rd. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 1993; 61: 719-28.
37. Shinoda I, Takase M, Fukuwatari Y, Shimamura S, Koller M, Konig W. Effects of lactoferrin and lactoferricin on the release of interleukin 8 from human polymorphonuclear leukocytes. Biosci Biotechnol Biochem 1996; 60: 521-3.
38. Mattsby-Baltzer I, Roseanu A, Motas C, Elverfors J, Engberg I, Hanson LA. Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res 1996; 40: 257-62.
39. Britigan BE, Lewis TS, Waldschmidt M, McCormick ML, Krieg AM. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J Immunol 2001; 167: 2921-8.
40. Samuelsen O, Haukland HH, Ulvatne H, Vorland LH. Anticomplement effects of lactoferrin-derived peptides. FEMS Immunol Med Microbiol 2004; 41: 141-8.
41. Adao R, Nazmi K, Bolscher JG, Bastos M. C-and Ntruncated antimicrobial peptides from LFampin 265-284: Biophysical versus microbiology results. J Pharm Bioallied Sci 2011; 3: 60-9.
42. van der Kraan MI, Nazmi K, van 't Hof W, Amerongen AV, Veerman EC, Bolscher JG. Distinct bactericidal activities of bovine lactoferrin peptides LFampin 268-284 and LFampin 265-284: Asp-Leu-Ile makes a difference. Biochem Cell Biol 2006; 84: 358-62.
43. Spillmann D. Heparan sulfate: Anchor for viral intruders? Biochimie 2001; 83: 811-7.
44. Mardberg K, Trybala E, Tufaro F, Bergstrom T. Herpes simplex virus type 1 glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing gro2C cells. J Gen Virol 2002; 83: 291-300.
45. Song BH, Lee GC, Moon MS, Cho YH, Lee CH. Human cytomegalovirus binding to heparan sulfate proteoglycans on the cell surface and/or entry stimulates the expression of human leukocyte antigen class I. J Gen Virol 2001; 82: 2405-13.
46. Argyris EG, Acheampong E, Nunnari G, Mukhtar M, Williams KJ, Pomerantz RJ. Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. J Virol 2003; 77: 12140-51.
47. Trybala E, Roth A, Johansson M, et al. Glycosaminoglycanbinding ability is a feature of wild-type strains of herpes simplex virus type 1. Virology 2002; 302: 413-9.
48. Cheshenko N, Herold BC. Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. J Gen Virol 2002; 83: 2247-55.
49. Day PM, Lowy DR, Schiller JT. Heparan Sulfate-Independent Cell Binding and Infection with Furin-Precleaved Papillomavirus Capsids. J Virol 2008; 82: 12565-8.
50. Jenssen H, Andersen JH, Uhlin-Hansen L, Gutteberg TJ, Rekdal O. Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antiviral Res 2004; 61: 101-9.
51. Wu HF, Monroe DM, Church FC. Characterization of the Glycosaminoglycan-Binding Region of Lactoferrin. Arch Biochem Biophys 1995; 317: 85-92.
52. Shimazaki K, Tazume T, Uji K, et al. Properties of a heparinbinding peptide derived from bovine lactoferrin. J Dairy Sci 1998; 81: 2841-9.
53. Andersen JH, Jenssen H, Sandvik K, Gutteberg TJ. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J Med Virol 2004; 74: 262-71.
54. Futaki S, Nakase I, Taclokoro A, Takeuchi T, Jones AT. Arginine-rich peptides and their internalization mechanisms. Biochem Soc Trans 2007; 35: 784-7.
55. Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus. Antiviral Res 2004; 64: 119-26.
56. Yasin B, Wang W, Pang M, et al. theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol 2004; 78: 5147-56.
57. Vogel HJ, Schibli DJ, Jing WG, Lohmeier-Vogel EM, Epand RF, Epand RM. Towards a structure-function analysis of bovine lactoferricin and related tryptophan-and argininecontaining peptides. Biochem Cell Biol 2002; 80: 49-63.
58. Wu MH, Maier E, Benz R, Hancock REW. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 1999; 38: 7235-42.
59. Chapple DS, Hussain R, Joannou CL, et al. Structure and association of human lactoferrin peptides with Escherichia coli lipopolysaccharide. Antimicrob Agents Chemother 2004; 48: 2190-8.
60. Chapple DS, Mason DJ, Joannou CL, Odell EW, Gant V, Evans RW. Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coli serotype O111. Infect Immun 1998; 66: 2434-40.
61. Aguilera O, Ostolaza H, Quiros LM, Fierro JF. Permeabilizing action of an antimicrobial lactoferricin-derived peptide on bacterial and artificial membranes. FEBS Lett 1999; 462: 273-7.
62. Ulvatne H, Haukland HH, Olsvik O, Vorland LH. Lactoferricin B causes depolarization of the cytoplasmic membrane of Escherichia coli ATCC 25922 and fusion of negatively charged liposomes. FEBS Lett 2001; 492: 62-5.
63. Ulvatne H, Samuelsen O, Haukland HH, Kramer M, Vorland LH. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol Lett 2004; 237: 377-84.
64. Haukland HH, Ulvatne H, Sandvik K, Vorland LH. The antimicrobial peptides lactoferricin B and magainin 2 cross over the bacterial cytoplasmic membrane and reside in the cytoplasm. FEBS Lett 2001; 508: 389-93.
65. Tu YH, Ho YH, Chuang YC, Chen PC, Chen CS. Identification of Lactoferricin B Intracellular Targets Using an Escherichia coli Proteome Chip. PLoS One 2011; 6: e28197.
66. Ho YH, Sung TC, Chen CS. Lactoferricin B Inhibits the Phosphorylation of the Two-Component System Response Regulators BasR and CreB. Mol Cell Proteomics 2012; 11: M111.014720.
67. van der Kraan MIA, van Marle J, Nazmi K, et al. Ultrastructural effects of antimicrobial peptides from bovine lactoferrin on the membranes of Candida albicans and Escherichia coli. Peptides 2005; 26: 1537-42.
68. Li J, Revol JF, Naranjo E, Marchessault RH. Effect of electrostatic interaction on phase separation behaviour of chitin crystallite suspensions. Int J Biol Macromol 1996; 18: 177-87.
69. de Lucca AJ, Walsh TJ. Antifungal peptides: Novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother 1999; 43: 1-11.
70. Yan DY, Chen D, Shen J, Xiao GZ, Van Wijnen AJ, Im HJ. Bovine lactoferricin is anti-inflammatory and anti-catabolic in human articular cartilage and synovium. J Cell Physiol 2013; 228: 447-56.
71. Yan DY, Chen D, Hawse JR, van Wijnen AJ, Im HJ. Bovine lactoferricin induces TIMP-3 via the ERK1/2-Sp1 axis in human articular chondrocytes. Gene 2013; 517: 12-8.
72. Kang JH, Lee MK, Kim KL, Hahm KS. Structure-biological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. Int J Pept Prot Res 1996; 48: 357-63.
73. Kuwata H, Yip TT, Yip CL, Tomita M, Hutchens TW. Bactericidal domain of lactoferrin: Detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry. Biochem Biophys Res Commun 1998; 245:764-73.
74. Strom MB, Rekdal O, Svendsen JS. Antibacterial activity of 15-residue lactoferricin derivatives. J Pept Res 2000; 56: 265-74.
75. Lopez-Soto F, Leon-Sicairos N, Nazmi K, Bolscher JG, de la Garza M. Microbicidal effect of the lactoferrin peptides Lactoferricin17-30, Lactoferrampin265-284, and Lactoferrin chimera on the parasite Entamoeba histolytica. Biometals 2010; 23: 563-8.
76. Azuma M, Kojima T, Yokoyama I, et al. Antibacterial activity of multiple antigen peptides homologous to a loop region in human lactoferrin. J Pept Res 1999; 54: 237-41.
77. Strom MB, Rekdal O, Svendsen JS. The effects of charge and lipophilicity on the antibacterial activity of undecapeptides derived from bovine lactoferricin. J Pept Sci 2002; 8: 36-43.
78. Strom MB, Rekdal O, Svendsen JS. Antimicrobial activity of short arginine-and tryptophan-rich peptides. J Pept Sci 2002; 8: 431-7.
79. Daidone I, Magliano A, Di Nola A, et al. Conformational study of bovine lactoferricin in membrane-micking conditions by molecular dynamics simulation and circular dichroism. Biometals 2011; 24: 259-68.
80. Haney EF, Nazmi K, Bolscher JGM, Vogel HJ. Influence of specific amino acid side-chains on the antimicrobial activity and structure of bovine lactoferrampin. Biochem Cell Biol 2012; 90: 362-77.
81. Haney EF, Lau F, Vogel HJ. Solution structures and model membrane interactions of lactoferrampin, an antimicrobial peptide derived from bovine lactoferrin. Biochim Biophys Acta 2007; 1768: 2355-64.
82. Fjell CD, Hiss JA, Hancock RE, Schneider G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 2011; 11: 37-51.
83. Silva T, Abengozar MA, Fernandez-Reyes M, et al. Enhanced leishmanicidal activity of cryptopeptide chimeras from the active N1 domain of bovine lactoferrin. Amino Acids 2012; 43: 2265-77.
84. Liu Y, Han F, Xie Y, Wang Y. Comparative antimicrobial activity and mechanism of action of bovine lactoferricinderived synthetic peptides. Biometals 2011; 24: 1069-78.
85. Jenssen H. Antimicrobial Activity of Lactoferrin and Lactoferrin Derived Peptides. 2009.
86. Bolscher JGM, Adao R, Nazmi K, et al. Bactericidal activity of Lfchimera is stronger and less sensitive to ionic strength than its constituent lactoferricin and lactoferrampin peptides. Biochimie 2009; 91: 123-32.
87. van der Kraan MIA, Nazmi K, Teeken A, et al. Lactoferrampin, an antimicrobial peptide of bovine lactoferrin, exerts its candidacidal activity by a cluster of positively charged residues at the C-terminus in combination with a helix-facilitating N-terminal part. Biol Chem 2005; 386: 137-42.
88. Rathinakumar R, Walkenhorst WF, Wimley WC. Broadspectrum antimicrobial peptides by rational combinatorial design and high-throughput screening: the importance of interfacial activity. J Am Chem Soc 2009; 131: 7609-17.
89. Haug BE, Svendsen JS. The role of tryptophan in the antibacterial activity of a 15-residue bovine lactoferricin peptide. J Pept Sci 2001; 7: 190-6.
90. Haug BE, Skar ML, Svendsen JS. Bulky aromatic amino acids increase the antibacterial activity of 15-residue bovine lactoferricin derivatives. J Pept Sci 2001; 7: 425-32.
91. Haug BE, Strom MB, Svendsen JS. The medicinal chemistry of short lactoferricin-based antibacterial peptides. Curr Med Chem 2007; 14: 1-18.
92. Vorland LH, Ulvatne H, Andersen J, et al. Antibacterial effects of lactoferricin B. Scand J Infect Dis 1999; 31: 179-84.
93. Karstad R, Isaksen G, Brandsdal BO, Svendsen JS, Svenson J. Unnatural Amino Acid Side Chains as S1, S1', and S2' Probes Yield Cationic Antimicrobial Peptides with Stability toward Chymotryptic Degradation (vol 53, pg 5558, 2010). J Med Chem 2010; 53: 5558-66.
94. Raguse TL, Porter EA, Weisblum B, Gellman SH. Structureactivity studies of 14-helical antimicrobial beta-peptides: Probing the relationship between conformational stability and antimicrobial potency. J Am Chem Soc 2002; 124: 12774-85.
95. Wakabayashi H, Matsumoto H, Hashimoto K, Teraguchi S, Takase M, Hayasawa H. N-acylated and D enantiomer derivatives of a nonamer core peptide of lactoferricin B showing improved antimicrobial activity. Antimicrob Agents Chemother 1999; 43: 1267-9.
96. Romo TD, Bradney LA, Greathouse DV, Grossfield A. Membrane binding of an acyl-lactoferricin B antimicrobial peptide from solid-state NMR experiments and molecular dynamics simulations. Biochim Biophys Acta 2011; 1808: 2019-30.
97. Zweytick D, Deutsch G, Andra J, et al. Studies on lactoferricin-derived Escherichia coli membrane-active peptides reveal differences in the mechanism of N-acylated versus nonacylated peptides. J Biol Chem 2011; 286: 21266-76.
98. Zweytick D, Pabst G, Abuja PM, et al. Influence of Nacylation of a peptide derived from human lactoferricin on membrane selectivity. Biochim Biophys Acta 2006; 1758: 1426-35.
99. Greathouse D, Vostrikov V, McClellan N, et al. Lipid interactions of acylated tryptophan-methylated lactoferricin peptides by solid-state NMR. J Pept Sci 2008; 14: 1103-10.
100. [100] Nguyen LT, Schibli DJ, Vogel HJ. Structural studies and model membrane interactions of two peptides derived from bovine lactoferricin. J Pept Sci 2005; 11: 379-89.
101. [101] Flores-Villasenor H, Canizalez-Roman A, de la Garza M, Nazmi K, Bolscher JGM, Leon-Sicairos N. Lactoferrin and lactoferrin chimera inhibit damage caused by enteropathogenic Escherichia coli in HEp-2 cells. Biochimie 2012; 94: 1935-42.
102. [102] Leon-Sicairos N, Canizalez-Roman A, de la Garza M, et al. Bactericidal effect of lactoferrin and lactoferrin chimera against halophilic Vibrio parahaemolyticus. Biochimie 2009; 91: 133-40.
103. [103] Flores-Villasenor H, Canizalez-Roman A, Reyes-Lopez M, et al. Bactericidal effect of bovine lactoferrin, LFcin, LFampin and LFchimera on antibiotic-resistant Staphylococcus aureus and Escherichia coli. Biometals 2010; 23: 569-78.
104. [104] Xu G, Xiong W, Hu Q, et al. Lactoferrin-derived peptides and Lactoferricin chimera inhibit virulence factor production and biofilm formation in Pseudomonas aeruginosa. J Appl Microbiol 2010; 109: 1311-8.
105. [105] Flores-Villasenor H, Canizalez-Roman A, Velazquez-Roman J, Nazmi K, Bolscher JGM, Leon-Sicairos N. Protective effects of lactoferrin chimera and bovine lactoferrin in a mouse model of enterohaemorrhagic Escherichia coli O157:H7 infection. Biochem Cell Biol 2012; 90: 405-11.
106. [106] Silva T, Abengozar MA, Fernandez-Reyes M, et al. Enhanced leishmanicidal activity of cryptopeptide chimeras from the active N1 domain of bovine lactoferrin. Amino Acids 2012; 43: 2265-77.
107. [107] Haney EF, Nazmi K, Bolscher JGM, Vogel HJ. Structural and biophysical characterization of an antimicrobial peptide chimera comprised of lactoferricin and lactoferrampin. Biochim Biophys Acta 2012; 1818: 762-75.
108. [108] Dewan PC, Anantharaman A, Chauhan VS, Sahal D. Antimicrobial Action of Prototypic Amphipathic Cationic Decapeptides and Their Branched Dimers. Biochemistry 2009; 48: 5642-57.
109. [109] Yang ST, Kim JI, Shin SY. Effect of dimerization of a betaturn antimicrobial peptide, PST13-RK, on antimicrobial activity and mammalian cell toxicity. Biotechnol Lett 2009; 31: 233-7.
110. [110] Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001; 1: 156-64.
111. [111] Wu M, Maier E, Benz R, Hancock RE. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 1999; 38: 7235-42.
112. [112] Haney EF, Nazmi K, Bolscher JG, Vogel HJ. Structural and biophysical characterization of an antimicrobial peptide chimera comprised of lactoferricin and lactoferrampin. Biochim Biophys Acta 2012; 1818: 762-75.
113. [113] Flores-Villasenor H, Canizalez-Roman A, de la Garza M, Nazmi K, Bolscher JG, Leon-Sicairos N. Lactoferrin and lactoferrin chimera inhibit damage caused by enteropathogenic Escherichia coli in HEp-2 cells. Biochimie 2012; 94: 1935-42.
114. [114] Huo L, Zhang K, Ling J, et al. Antimicrobial and DNA-binding activities of the peptide fragments of human lactoferrin and histatin 5 against Streptococcus mutans. Arch Oral Biol 2011; 56: 869-76.
115. [115] Vogel HJ, Schibli DJ, Jing W, Lohmeier-Vogel EM, Epand RF, Epand RM. Towards a structure-function analysis of bovine lactoferricin and related tryptophan-and argininecontaining peptides. Biochem Cell Biol 2002; 80: 49-63.
116. [116] Ulvatne H, Samuelsen O, Haukland HH, Kramer M, Vorland LH. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol Lett 2004; 237: 377-84.
117. [117] Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial Spectrum of Lactoferricin-B, a Potent Bactericidal Peptide Derived from the N-Terminal Region of Bovine Lactoferrin. J Appl Bacteriol 1992; 73: 472-9.
118. [118] Nguyen LT, Chau JK, Perry NA, de Boer L, Zaat SAJ, Vogel HJ. Serum Stabilities of Short Tryptophan-and Arginine-Rich Antimicrobial Peptide Analogs. PLoS One 2010; 5. pii: e12684.
119. [119] Svenson J, Vergote V, Karstad R, Burvenich C, Svendsen JS, De Spiegeleer B. Metabolic Fate of Lactoferricin-Based Antimicrobial Peptides: Effect of Truncation and Incorporation of Amino Acid Analogs on the In Vitro Metabolic Stability. J Pharmacol Exp Ther 2010; 332: 1032-9.
120. [120] Haug BE, Strom MB, Svendsen JSM. The medicinal chemistry of short lactoferricin-based antibacterial peptides. Curr Med Chem 2007; 14: 1-18.
121. [121] Hunter HN, Jing WG, Schibli DJ, et al. The interactions of antimicrobial peptides derived from lysozyme with model membrane systems. Biochim Biophys Acta 2005; 1668: 175-89.
122. [122] Romo TD, Bradney LA, Greathouse DV, Grossfield A. Membrane binding of an acyl-lactoferricin B antimicrobial peptide from solid-state NMR experiments and molecular dynamics simulations. Biochim Biophys Acta 2011; 1808: 2019-30.
123. [123] Zweytick D, Pabst G, Abuja PM, et al. Influence of Nacylation of a peptide derived from human lactoferricin on membrane selectivity. Biochim Biophys Acta 2006; 1758: 1426-35.
124. [124] Nguyen LT, Chau JK, Perry NA, de Boer L, Zaat SA, Vogel HJ. Serum stabilities of short tryptophan-and arginine-rich antimicrobial peptide analogs. PLoS One 2010; 5. pii: e12684.
125. [125] Greathouse D, Vostrikov V, McClellan N, et al. Lipid interactions of acylated tryptophan-methylated lactoferricin peptides by solid-state NMR. J Pept Sci 2008; 14: 1103-10.
126. [126] Nguyen LT, Schibli DJ, Vogel HJ. Structural studies and model membrane interactions of two peptides derived from bovine lactoferricin. J Pept Sci 2005; 11: 379-89.
127. [127] Liu Y, Xia X, Xu L, Wang Y. Design of hybrid beta-hairpin peptides with enhanced cell specificity and potent antiinflammatory activity. Biomaterials 2013; 34: 237-50.
128. [128] Aoki W, Kitahara N, Miura N, Morisaka H, Kuroda K, Ueda M. Design of a novel antimicrobial peptide activated by virulent proteases. Chem Biol Drug Des 2012; 80: 725-33.
129. [129] Tang Z, Zhang Y, Stewart AF, et al. High-level expression, purification and antibacterial activity of bovine lactoferricin and lactoferrampin in Photorhabdus luminescens. Protein Expr Purif 2010; 73: 132-9.
130. [130] Tian ZG, Teng D, Yang YL, et al. Multimerization and fusion expression of bovine lactoferricin derivative LfcinB15-W4,10 in Escherichia coli. Appl Microbiol Biotechnol 2007; 75: 117-24.
131. [131] Feng X, Liu C, Guo J, et al. Expression and purification of an antimicrobial peptide, bovine lactoferricin derivative LfcinBW10 in Escherichia coli. Curr Microbiol 2010; 60: 179-84.
132. [132] Feng XJ, Wang JH, Shan AS, et al. Fusion expression of bovine lactoferricin in Escherichia coli. Protein Expr Purif 2006; 47: 110-7.
133. [133] Tang Z, Yin Y, Zhang Y, et al. Effects of dietary supplementation with an expressed fusion peptide bovine lactoferricin-lactoferrampin on performance, immune function and intestinal mucosal morphology in piglets weaned at age 21 d. Br J Nutr 2009; 101: 998-1005.